In a clinical trial being planned for hospitals in Massachusetts and Colorado, patients with severe cases of COVID-19 would be given the blood thinner tissue plasminogen activator (tPA), a protein prescribed for heart attack and stroke victims.
Get the full story on our sister site Drug Discovery and Development.